GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: Sonvuterkib is the INN for an extracellular signal-regulated kinases (ERK) inhibitor that was included in WHO INN proposed list 133 (10th July 2025). It is claimed as compound WX001 in patent WO2023274256A1, principally to target Ras/Raf/MEK/ERK pathway activation in tumours [1]. Sonvuterkib is potentially the INN for D3 Bio's dual ERK1/2 inhibitor clinical lead D3S-002 (structure not disclosed, July 2025).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Li Y, Yu T, Liu N, Wu C, Chen S. (2023)
Thiazole-lactam-spiroheterocyclic compounds and applications thereof. Patent number: WO2023274256A1. Assignee: MEDSHINE DISCOVERY INC.. Priority date: 28/06/2022. Publication date: 05/01/2023. |